Leading the charge to develop new, targeted approaches to treat disease, Children’s Hospital of Philadelphia Research Institute investigators have uncovered more of the mechanistic underpinnings of the migratory T cell response, and CHOP announced the inaugural Patricia Brophy Endowed Chair in Neuroblastoma Research to advance innovation into less toxic treatment options for specific cancers. Out in the community, CHOP has teamed up with the Philadelphia Housing Development Corporation for the pilot program of its Healthier Together initiative, and researchers are learning how best to help survivors of violence after they are discharged from the hospital.
Tag Archive: Alex’s Lemonade Stand Foundation
With the release of over 200 genomic tumor models spanning 25 different types of childhood cancer, researchers may now have the ability to skip lengthy preclinical work in their development of novel treatments. With funding from Alex’s Lemonade Stand Foundation (ALSF), the Pediatric Preclinical Testing Consortium (PPTC) announced their data sets will now be made available to any qualified academic petitioner — a move that John Maris, MD, oncologist at Children’s Hospital of Philadelphia Cancer Center and principal investigator of the PPTC’s CHOP site, believes is the first of its kind.
Acute myeloid leukemia (AML), the second most common leukemia in children, affects different populations of pediatric patients in different ways. With the support of a new Epidemiology Grant from Alex’s Lemonade Stand Foundation, Richard Aplenc, MD, PhD, assistant vice president and chief clinical research officer at Children’s Hospital of Philadelphia, is leading a powerful research project based on the automated extraction of data to learn more about racial and ethnic disparities observed in African American children with AML.
“We’ve known for a long time that African American children do worse with treatment for acute myeloid leukemia than non-African American children,” Dr. Aplenc said. “But we’ve never really understood why that is, and there are a lot of different possibilities.”
In this week’s roundup of headlines at Children’s Hospital of Philadelphia, our research takes a leap into real-world applications. Learn how a study from ear, nose, and throat experts at CHOP helped to inform new button battery injury guidelines from the National Poison Center, why a software tool that mines through genomics data can improve genetic diagnoses, and what PolicyLab plans to achieve at their upcoming 10thanniversary forum, “Charting New Frontiers in Children’s Health Policy and Practice.” Don’t miss a chance to discover the latest in research news!
Summer at Children’s Hospital of Philadelphia is definitely off to a sweet start: We kick off this week’s research roundup with a new way of thinking about honey (thanks to novel findings from our ear, nose, and throat specialists) and congratulate the Cancer Center at CHOP on yet another successful day of serving up lemonade to support the Alex’s Lemonade Stand Foundation (ALSF). On top of that, we cover research updates from our Mitochondrial Medicine Frontier Program and the Center for Autism Research (CAR), and share a special new award for Stephan Grupp, MD, PhD, director of the Cancer Immunotherapy Program.
It was a big year for children’s health: We celebrated the U.S. Food and Drug Administration’s approval of the world’s first chimeric antigen receptor (CAR)-T cell therapy this September, followed closely by approval of the very first gene therapy to treat inherited blindness this month — both of which have their roots at Children’s Hospital of Philadelphia and the University of Pennsylvania. But besides the big headline-making breakthroughs (brilliant as they are), we wanted to know what other stories captivated our readers in 2017.